AM 285

Drug Profile

AM 285

Alternative Names: Cyclocreatine

Latest Information Update: 11 Nov 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Repligen
  • Developer Amira; Repligen
  • Class Anti-ischaemics; Antineoplastics; Antivirals; Imidazolidines; Small molecules
  • Mechanism of Action Creatine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Cytomegalovirus infections; Herpes simplex virus infections

Most Recent Events

  • 11 Nov 2003 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 11 Nov 2003 Discontinued - Preclinical for Cytomegalovirus infections treatment in USA (unspecified route)
  • 11 Nov 2003 Discontinued - Preclinical for Herpes simplex virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top